Business Wire

NY-HCL-GROUP

20.9.2022 23:45:31 CEST | Business Wire | Press release

Share
HCL and UpLink Call for Applications Globally for Aquapreneur Innovation Initiative

HCL, a global conglomerate and UpLink, the open innovation platform of the World Economic Forum, announced today that applications have opened for the Global Freshwater Innovation Challenge. This is the first out of five Challenges of the HCL and UpLink’s Aquapreneur Innovation Initiative, a programme to source innovative solutions to conserve and restore freshwater ecosystems, from ‘aquapreneurs’ (water focused entrepreneurs). The Initiative, launched during the Forum’s Annual Meeting in Davos in May 2022, will create a first-of-its-kind innovation ecosystem for the global freshwater sector. The last date to apply is November 08, 2022. Full details and eligibility criteria can be found at this link. HCL has committed $15 million over five years to support the water focused entrepreneurs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220920005992/en/

Roshni Nadar Malhotra, Chairperson of HCL Technologies said, “An innovation ecosystem can enable water entrepreneurs with resources and mentoring to invest in creating new solutions and improving any existing ones for scale and impact. There are entrepreneurs and start-ups that have the potential to provide contextualized solutions to conserve freshwater and have been trying to create impact in small ways within small ecosystems. Out of these, many struggle to secure financing and lack the operational capacity to scale their solutions. HCL, through its large network and partnership with the World Economic Forum’s UpLink, is keen to ensure that these entrepreneurs are identified and supported.”

The first year’s challenge, called the Global Freshwater Challenge, will focus on:

  • Improved decision-making: solutions that fill knowledge gaps, improve data collection, and create transparent and accessible data (i.e., solutions that monitor and forecast water use & demand)
  • Water quality restoration: solutions that tackle water quality by monitoring, treating, restoring or protecting it. (i.e. solutions such as solar distillers for water purification)
  • Ecosystem resilience: solutions that protect source waters across the value chain and strengthen resilience to climate and weather-related shocks, taking into consideration the most vulnerable areas at risk (i.e. solutions that reduce water evapotranspiration from extreme heat, or ways to absorb and store acute flooding)

Gim Huay Neo, Managing Director of the Centre for Nature and Climate at the World Economic Forum says, “The Aquapreneur Innovation Initiative invites all entrepreneurs to participate to scale and accelerate their solutions and impact. Through this initiative, we seek to enhance freshwater resilience and better protect our water resource. The collaboration with HCL and UpLink will provide a platform for the top innovators to connect with public and private partners, as well as gain access to venture funds, to jointly transform our sustainable management and use of freshwater systems.”

HCL and UpLink are looking for:

  • Stage: Impact-oriented start-ups that are at pilot, growth or scale-up phase, with demonstrated success towards scale (i.e., a proven track record with measurable results and impact). Solutions that represent an “idea” or “prototype” phase will not be considered.
  • Business Model: Ideally seeking for-profit start-up companies or social enterprises with a sustainable, and ideally hybrid, funding model.
  • Scale: Start-ups which demonstrate the potential to scale, particularly for communities most impacted, alongside a vision for achieving long-term financial viability and sustainability.

Selected entrepreneurs will have the opportunity to work closely with industry experts, investors, and ecosystem partners to further develop their innovative solution, to scale and drive further impact.

About HCL Group

Founded in 1976 as one of India’s original IT garage start-ups, HCL is a pioneer of modern computing with many firsts to its credit, including the introduction of the 8-bit microprocessor-based computer in 1978 well before its global peers. Today, the HCL Group has business presence across sectors including technology and healthcare and comprises three group companies – HCL Technologies, HCL Infosystems and HCL Healthcare. The Group generates annual revenues of over US$11.8 billion with more than 211,000 employees operating across 52 countries.

HCL Technologies, a group company, empowers global enterprises with technology for the next decade, today. As a leading global technology company, it takes pride in its diversity, social responsibility, sustainability and education initiatives. HCL Technologies is also a strategic partner of the World Economic Forum.

About UpLink

UpLink is the open innovation platform of the World Economic Forum, dedicated to unlocking an ‘entrepreneur revolution’ to support positive systemic change for people and planet. Launched at the Forum’s Annual Meeting in Davos in January 2020 in collaboration with Salesforce and Deloitte, UpLink is now a thriving ecosystem of 50,000+ entrepreneurs, investors and experts, who are collaborating around innovation for the UN Sustainable Development Goals.

For further information, visit www.hcl.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220920005992/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye